#4 - Amgen (NASDAQ:AMGN)
The next stock on our list has a similar story to AbbVie. That is, Amgen (NASDAQ:AMGN) has several high-revenue generating products in the market. Some of the most common names are Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta which reduces the chance of infection for cancer patients; and Otezla which is also used to treat plaque psoriasis and psoriatic arthritis.
Although AMGN doesn’t have as attractive of a technical setup at the moment, the stock does appear to be forming a level of support of around $197. If that proves to be the case, then investors may have reason to believe the analyst's forecast for a price target of around $230 will be accurate. And in the meantime, Amgen is offering an attractive dividend for sticking around. The company currently pays out $7.04 on an annual basis and the company has increased its dividend in each of the last 10 years.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More - Current Price
- $263.38
- Consensus Rating
- Hold
- Ratings Breakdown
- 11 Buy Ratings, 12 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $319.67 (21.4% Upside)
